Purpose: Platinum-based regimens represent the standard first-line treatment for non-small-cell lung cancer (SNCLC). However, newer data have established a role for pemetrexed in the treatment of this disease. Such data suggest that histology represents a determining factor in the selection of treatment. Methods: We undertook a systematic review of the literature for randomized controlled trials that compared the efficacy of pemetrexed with that of other treatments in advanced SNCLC. Data and study quality were assessed according to published guidelines. Results: We identified five trials that compared pemetrexed with other treatments or with placebo. Overall survival for patients treated with pemetrexed was superior to that with other treatments: hazard ratio (HR): 0.89; 95% confidence interval (CI): 0.80 to 0.99. The survival benefit was limited to patients with non-squamous histology: hr: 0.82; 95% ci: 0.73 to 0.91. Pemetrexed was inferior to other chemotherapy options in patients with squamous histology: hr: 1.19; 95% ci: 0.99 to 1.43. Conclusions: Compared with other chemotherapy agents, pemetrexed is more effective for the treatment of SNCLC in patients with non-squamous histology.
from across Eastern Canada for the purpose of recommending management strategies for patients with colorectal cancer (crc) and other selected gastrointestinal cancers.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.